MajesTEC-5
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
- NCT05695508 ↗
- Recruiting
- University of Heidelberg Medical Center
- Deep
We haven't built an HCP commentary report on MajesTEC-5 (teclistamab plus daratumumab plus lenalidomide plus dexamethasone; talquetamab plus daratumumab plus lenalidomide plus dexamethasone; ramantamig (JNJ-79635322) plus daratumumab plus lenalidomide plus dexamethasone in transplant-eligible newly diagnosed multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MajesTEC-5 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 51 | |
| YouTube | 31 | |
| Bluesky threads | 14 | |
| Podcasts | 13 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants With Newly Diagnosed Transplant Eligible Multiple Myeloma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab (Tec); Daratumumab; Dexamethasone; Lenalidomide; Bortezomib; Talquetamab; JNJ-79635322
- Arms
- Arm A Tec-DRd Induction and Tec-D Maintenance · Experimental
- Arm B Tec-DVRd Induction and Tec-D Maintenance · Experimental
- Arm C Tec-D Maintenance · Experimental
- Arm A1 Tec-DRd Induction and Tec-D Maintenance · Experimental
- Arm C2 Tal-DR Maintenance · Experimental
- Arm D Tec-DRd Induction and Tec-Tal following induction · Experimental
- Arm E Tal-DRd Induction and Tec-D Maintenance · Experimental
- Arm E1 Tal-DRd Induction and Tal-D Maintenance · Experimental
- Arm F Tal-DVRd Induction and Tec-D Maintenance · Experimental
- Arm F1 Tal-DVRd Induction and Tal-D Maintenance · Experimental
- Arm-G JNJ-79635322-DRd induction - JNJ-79635322-D following ind · Experimental
- Enrollment
- 160 (estimated)
- Primary outcomes
- number of incidence and severity of adverse events [safety and tolerability]
- Sponsor
- University of Heidelberg Medical Center with Janssen Research & Development, LLC, Deutsche Studiengruppe Multiples Myelom (DSMM)
- Start
- Dec 1, 2022
- Primary completion
- Sep 15, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05695508 · updated Dec 24, 2025
Publications
linked from the registry- Raab MS, Weinhold N, Kortum KM, Kronke J, Fenk R, Weisel K, Podola L, Bertsch U, Brobeil A, Mersi J, Huhn S, Arlinghaus R, Hundemer M, Bohl SR, Mai EK, Schub N, Waldschmidt J, Bassermann F, Muller-Tidow C, Heuck C, Sakabedoyan C, Khan J, Ershova E, Koster BD, Engelhardt M, Hanel M, Salwender H, Teipel R, Goldschmidt H, Einsele H, Rasche L; GMMG-HD10/DSMM-XX (MajesTEC-5) investigators. Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial. Nat Med. 2026 Jul;32(7):2440-2448. doi: 10.1038/s41591-026-04471-x. Epub 2026 Jun 25. PubMed 42350642